

Timor-Leste

Population 2017

1.3 million

Estimates of TB burden*, 2017	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	1.4 (0.81–2.1)	106 (63–161)
Mortality (HIV+TB only)	<0.01 (<0.01–0.019)	0.46 (0.03–1.5)
Incidence (includes HIV+TB)	6.5 (4.2–9.2)	498 (322–711)
Incidence (HIV+TB only)	0.059 (0.037–0.085)	4.5 (2.9–6.6)
Incidence (MDR/RR-TB)**	0.26 (0.089–0.52)	20 (6.9–40)

Estimated TB incidence by age and sex (thousands)*, 2017			
	0-14 years	> 14 years	Total
Females	0.38 (0.34–0.42)	2.2 (1.7–2.7)	2.6 (1.9–3.2)
Males	0.42 (0.38–0.46)	3.5 (2.5–4.5)	3.9 (2.7–5.1)
Total	0.8 (0.69–0.91)	5.7 (3.6–7.7)	6.5 (4.2–9.2)

TB case notifications, 2017	
Total cases notified	3 579
Total new and relapse	3 470
- % tested with rapid diagnostics at time of diagnosis	11%
- % with known HIV status	77%
- % pulmonary	83%
- % bacteriologically confirmed among pulmonary	68%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2017	54% (38–83)
TB patients facing catastrophic total costs, 2017	83%
TB case fatality ratio (estimated mortality/estimated incidence), 2017	0.22 (0.11–0.36)

TB/HIV care in new and relapse TB patients, 2017		
	Number	(%)
Patients with known HIV-status who are HIV-positive	25	<1%
- on antiretroviral therapy	25	100%

Drug-resistant TB care, 2017			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			130 (55–200)
Estimated % of TB cases with MDR/RR-TB	3.3% (1.2–6.4)	18% (11–26)	
% notified tested for rifampicin resistance	11%	0%	366
MDR/RR-TB cases tested for resistance to second-line drugs			4
Laboratory-confirmed cases		MDR/RR-TB: 4, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 4, XDR-TB: 0	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2016	89%	3 718
Previously treated cases, excluding relapse, registered in 2016	85%	13
HIV-positive TB cases registered in 2016	91%	23
MDR/RR-TB cases started on second-line treatment in 2015	50%	4
XDR-TB cases started on second-line treatment in 2015		0

TB preventive treatment, 2017	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	96% (88–100)

TB financing, 2018	
National TB budget (US\$ millions)	1.8
Funding source: 0% domestic, 100% international, 0% unfunded	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2017




Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



— Unfunded
— Funded internationally
— Funded domestically